$34.49
-0.66-1.88%
Last update: Oct 23, 4:00 PM
UroGen Pharma Ltd (URGN) Stock Price, Quote, News & History
URGNNASDAQ
FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.
You can purchase shares of UroGen Pharma (NASDAQ:URGN) through any online brokerage.
Other companies in UroGen Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
UroGen Pharma has a consensus price target of $38.77.
The stock price for UroGen Pharma (NASDAQ: URGN) is $34.49 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for UroGen Pharma.
UroGen Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for UroGen Pharma.
UroGen Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing...
